BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 58.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,574 shares of the biotechnology company's stock after selling 124,092 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in BioMarin Pharmaceutical were worth $5,691,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 144.3% in the 2nd quarter. AQR Capital Management LLC now owns 55,372 shares of the biotechnology company's stock worth $4,559,000 after buying an additional 32,709 shares during the period. Creative Planning increased its stake in BioMarin Pharmaceutical by 4.6% during the second quarter. Creative Planning now owns 11,825 shares of the biotechnology company's stock worth $974,000 after acquiring an additional 524 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 3,931.5% in the 2nd quarter. NewEdge Advisors LLC now owns 10,885 shares of the biotechnology company's stock worth $896,000 after purchasing an additional 10,615 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $1,783,000. Finally, Handelsbanken Fonder AB grew its holdings in shares of BioMarin Pharmaceutical by 2.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 124,022 shares of the biotechnology company's stock worth $8,718,000 after purchasing an additional 2,456 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Up 0.2 %

Shares of BioMarin Pharmaceutical stock traded up $0.16 during trading on Thursday, reaching $64.34. The company had a trading volume of 1,143,559 shares, compared to its average volume of 1,627,132. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. BioMarin Pharmaceutical Inc. has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The firm's fifty day moving average is $65.04 and its 200-day moving average is $72.46. The company has a market cap of $12.26 billion, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 0.55 and a beta of 0.28.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares in the company, valued at $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on BMRN. Canaccord Genuity Group cut their price target on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating on the stock in a report on Wednesday, October 30th. Royal Bank of Canada reissued a "sector perform" rating and issued a $80.00 target price on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. JPMorgan Chase & Co. decreased their price target on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a research report on Wednesday, October 30th. Evercore ISI cut their price objective on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. Finally, Wolfe Research initiated coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They issued an "outperform" rating and a $95.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $94.20.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.